IMUX FY 2022 Earnings — Immunic, Inc. Revenue & Financial Results | Market Cap Arena

IMUXImmunic, Inc.

$135M

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$119M

Net Income

-$120M

EPS (Diluted)

$-3.78

Cash Flow

Operating Cash Flow

-$65M

Free Cash Flow

-$65M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$128M

Total Liabilities

$14M

Stockholders' Equity

$114M

Cash & Equivalents

$107M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$119M	-$92M	-30.4%
Net Income	-$120M	-$93M	-29.5%